Repligen Corp. (NASDAQ:RGEN) shares traded down 3.4% on Tuesday . The stock traded as low as $25.98 and last traded at $26.07, with a volume of 55,732 shares trading hands. The stock had previously closed at $26.98.

Several research analysts have weighed in on the company. Jefferies Group reiterated a “hold” rating and issued a $28.00 target price on shares of Repligen Corp. in a research note on Monday, June 13th. Zacks Investment Research downgraded Repligen Corp. from a “hold” rating to a “sell” rating in a research note on Wednesday, June 8th.

The firm’s 50-day moving average is $24.96 and its 200 day moving average is $25.22. The company has a market cap of $876.61 million and a P/E ratio of 108.58.

Repligen Corp. (NASDAQ:RGEN) last announced its earnings results on Thursday, May 5th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.02. During the same quarter in the previous year, the company earned $0.12 EPS. The business had revenue of $25.10 million for the quarter, compared to analyst estimates of $22.54 million. The business’s revenue for the quarter was up 20.5% on a year-over-year basis. Analysts predict that Repligen Corp. will post $0.47 earnings per share for the current fiscal year.

In other Repligen Corp. news, Director Thomas F. Ryan, Jr. sold 10,000 shares of the stock in a transaction that occurred on Tuesday, June 28th. The shares were sold at an average price of $24.59, for a total transaction of $245,900.00. Following the transaction, the director now owns 27,094 shares in the company, valued at approximately $666,241.46. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Thomas F. Ryan, Jr. sold 5,000 shares of the stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $26.60, for a total transaction of $133,000.00. Following the transaction, the director now owns 12,094 shares in the company, valued at approximately $321,700.40. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have made changes to their positions in the company. Russell Frank Co raised its position in shares of Repligen Corp. by 12.7% in the fourth quarter. Russell Frank Co now owns 66,506 shares of the company’s stock worth $1,933,000 after buying an additional 7,498 shares during the last quarter. Nationwide Fund Advisors raised its stake in Repligen Corp. by 14.4% in the fourth quarter. Nationwide Fund Advisors now owns 82,025 shares of the company’s stock valued at $2,320,000 after buying an additional 10,350 shares in the last quarter. California State Teachers Retirement System raised its stake in Repligen Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 60,884 shares of the company’s stock valued at $1,722,000 after buying an additional 984 shares in the last quarter. Rhumbline Advisers raised its stake in Repligen Corp. by 9.4% in the fourth quarter. Rhumbline Advisers now owns 57,619 shares of the company’s stock valued at $1,630,000 after buying an additional 4,970 shares in the last quarter. Finally, OppenheimerFunds Inc. raised its stake in Repligen Corp. by 33.2% in the fourth quarter. OppenheimerFunds Inc. now owns 1,868,776 shares of the company’s stock valued at $52,867,000 after buying an additional 465,946 shares in the last quarter.

Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.